Kenyan Health Patient Information Leaflet
Melatonergic antidepressant
Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)). Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC. Major depressive episodes in adults.
25 mg OD orally before or food at bed-time. The dose may be increased to 50mg OD if there is no improvement of symptoms after 2wks. Treatment needs to proceed for at least 6 months.
Common: headache, dizziness, somnolence, insomnia, migraine, nausea, diarrhea, constipation, upper abdominal pain, hyperhidrosis, back pain, fatigue, increased serum transaminases. Uncommon: paraesthesia, blurred vision, erythematous rash; hepatitis [rare]
Store as labelled. Keep out of reach of children.